We believe in abetter future forpeople and theplanet.
At Sofinnova Partners, we focus on breakthrough innovations that have the potential to solve the world's most pressing problems. Experience, agility, and diverse points of view push us forward, driving our ability to evolve in a complex environment.
“Partners for Life” is a cornerstone of our identity: nurturing strong relationships through trust and transparency. We invest in people and science to create opportunity. We commit to long-term partnerships with entrepreneurs who are as passionate as we are about pushing the frontiers of innovation to contribute to a better future.
Founded in 1972, Sofinnova Partners has backed more than 500 companies over 50 years, creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management.
Sofinnova Partners is active across the entire value chain of life sciences investments, from seed to later-stage, with a focus on healthcare and sustainability. Each of our funds is a manifestation of our ability to recognize opportunity and unlock its potential with a dedicated team and a tailored strategic approach.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
Years of Experience
Euros in Assets Under Management
Distinct Fund Strategies
"We are known for being company creators. We continue to do what we know. Our strategy has evolved, but has remained consistent."
"If you treat patients, you save lives, ultimately this is going to be good for investors. We believe that by backing companies, whether early stage or later stage, that bring a product to patients — ultimately this translates into financial return."
“We have experience, a strong network, a good reputation for adding value to our portfolio companies — and the relationships between the CEOs of the portfolio companies and our partners are excellent.”
“I joined Sofinnova Partners because first of all, they have a fantastic brand in Europe, but it's easy to see it is a very strong partnership. They're loyal to each other and everyone knows they treat entrepreneurs well.”
Inspirna to present Phase 1b RGX-202-01 clinical trial data at the 2022 ESMO World Congress on Gastrointestinal Cancer￼
Avantium and Carlsberg sign offtake agreement on PEF
GlycoEra AG announces appointment of Tanmoy Ganguly, Ph.D., as Chief Scientific Officer
Cédric Moreau discusses Apollo deal on "Journal des Biotechs"
Moon Surgical raises $31.3 million to accelerate development of Maestro Robotic System